Business Context and Reporting Period
This Form 8-K reports a material definitive agreement entered into by Dianthus Therapeutics, Inc. on September 9, 2025. The filing details a public equity offering intended to close on September 11, 2025.
Key Financial Metrics
The filing discloses the following capital raise metrics:
- Common Stock Issued: 6,487,879 shares at $33.00 per share.
- Pre-Funded Warrants Issued: 1,112,121 warrants at $32.999 per share (exercisable at $0.001).
- Over-Allotment Option: Underwriters exercised the full option to purchase an additional 1,140,000 shares.
- Net Proceeds: Approximately $270.0 million after deducting underwriting discounts, commissions, and estimated offering expenses.
Note: This filing does not provide data on revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the execution of an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC, Evercore Group L.L.C., and Stifel, Nicolaus & Company, Incorporated. This transaction significantly increases the company's cash liquidity through the issuance of new equity and pre-funded warrants.
Outlook, Risks, and Contingencies
- Ownership Limits: Holders of Pre-Funded Warrants are restricted from exercising if they would beneficially own more than 4.99%, 9.99%, or 19.99% of outstanding shares, unless they provide 61 days' prior notice to increase this threshold.
- Indemnification: The Company agreed to indemnify the Underwriters against certain liabilities under the Securities Act of 1933.
- Closing Date: The Offering is expected to close on September 11, 2025.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received versus the estimated $270.0 million.
- Review the final prospectus supplement (filed September 11, 2025) for updated use of proceeds.
- Confirm the total number of shares outstanding post-offering to assess dilution impact.
- Check subsequent filings for any changes in the exercise of the Pre-Funded Warrants.